Abstract | PURPOSE: PATIENTS AND METHODS: Forty-four patients with stage IIIB/IV NSCLC were treated with a combination of tirapazamine and cisplatin. Patients received tirapazamine 260 mg/m2 administered intravenously over 2 hours, followed 1 hour later by cisplatin 75 mg/m2 administered over an additional hour, repeated every 21 days. The duration of therapy was meant to be limited to four cycles for nonresponders and eight cycles for responders. RESULTS: Ten of 44 patients (23%) showed a partial response. The estimated median survival for all patients was 37 weeks. Toxicities were treatable and included grade 3 nausea or vomiting (25%), fatigue (27.3%), and muscle cramps (4.5%). No dose reductions were necessary. CONCLUSION:
|
Authors | J Treat, E Johnson, C Langer, C Belani, B Haynes, R Greenberg, R Rodriquez, P Drobins, W Miller Jr, L Meehan, A McKeon, J Devin, R von Roemeling, J Viallet |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 16
Issue 11
Pg. 3524-7
(Nov 1998)
ISSN: 0732-183X [Print] United States |
PMID | 9817270
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Triazines
- Tirapazamine
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Cisplatin
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Survival Analysis
- Tirapazamine
- Treatment Outcome
- Triazines
(administration & dosage)
|